Ministry of Health Highlights Financial Implications of Treating Asthma Patients – TopNews New Zealand


Marlborough Express

Ministry of Health Highlights Financial Implications of Treating Asthma Patients
TopNews New Zealand
Revealing the shocking costs for the treatment of asthma, Ministry of Health has stated that it cost $1121 a day to treat a patient of asthma in hospital. According to the Asthma Foundation's President Professor Ian Town, it was one of the several ways
Asthma can't stop All Black dreamMarlborough Express
Asthma costs us in so many waysScoop.co.nz (press release)
Everyone Breathe Launches New Asthma Education Grant Program to Raise Business Wire (press release)

all 17 news articles »

View full post on asthma – Google News

Patients with asthma or allergies initially prescribed montelukast instead of … – pharmabiz.com

Patients with asthma or allergies initially prescribed montelukast instead of
pharmabiz.com
Patients with asthma or allergic rhinitis (nasal allergies), initially prescribed montelukast (Singulair) instead of typical first-line therapy have low rates of persistence on montelukast and may ultimately discontinue therapy altogether, according to

View full post on asthma – Google News

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for … – PR Newswire (press release)

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for
PR Newswire (press release)
Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis.

and more »

View full post on asthma – Google News

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for … – SYS-CON Media (press release)

Less than One-Third of Patients Taking Montelukast (Singulair®) Therapy for
SYS-CON Media (press release)
Montelukast is FDA-approved for treatment of asthma and allergic rhinitis. It works by inhibiting leukotrienes, the chemicals that cause inflammation. Montelukast is considered a second line of defense against asthma or allergic rhinitis.

View full post on asthma – Google News